Alpha 1 Global

Our mission is to develop a collaborative global network of Alpha-1 patient leaders, physicians, and researchers, to increase awareness, detection, and access to care for Alphas around the world.


The EU’s Cross-border healthcare directive and you – an Alpha-1 patient’s chance for a better life

Cross-border healthcare in the European Union – what’s it all about? Every patient suffering from a rare disease is painfully familiar with the struggle of …

Read More

Alpha-1 Global is developing a new Alpha-1 Advocacy Pathway

Advocacy and policy can improve diagnosis and treatment of Alpha-1 patients. In order to encourage and facilitate Alpha-1 patients advocacy efforts, Alpha-1 Global has started …

Read More

The Patient Perspective of Alpha-1 Antitrypsin Deficiency: Disease Burden and Unmet Needs

The European Respiratory Society has recently published their latest article of Breathe, a clinical educational publication, which features a story centered on the lives of …

Read More

Long Harbour man is in a deadly waiting game with Newfoundland and Labrador government over treatment for rare disease

Alpha-1 antitrypsin deficiency means Chris Williams has grim prospects without replacement therapy the province’s drug plan won’t cover LONG HARBOUR, N.L. — Chris Williams’ life has …

Read More

RESPREEZA® Alpha-1 Proteinase Inhibitor (Human) Update

The following is a statement from CSL Behring regarding RESPREEZA® in the European Union: February 8, 2021 – As a precautionary measure, CSL Behring has …

Read More

CSL Behring Announces EU LEAD Grants for Advocacy Development

Dear EU Alpha-1 Global Partners, We are pleased to provide you information regarding CSL Behring’s announcement for Local Empowerment for Advocacy Development (LEAD) Grants available …

Read More

PPTA urges decisive action in Europe to increase plasma donations

Shortfalls in donations due to COVID-19 could threaten patient access Brussels, (October 6, 2020) — International Plasma Awareness Week (IPAW) takes on particular urgency this …

Read More

PatientAdvocacy.Academy seeks Young Alpha-1 Patient Leaders for Exciting Advocacy Program

The PatientAdvocacy.Academy, an online learning platform designed for patient leaders in the field of plasma derived therapies, is looking for EU Alpha-1 patient leaders to …

Read More

Future access to Plasma Derived Medicinal Products: Patient Centred Decision Making

29 September 2020, 15:00 – 16:30 hrs Online event co-organised with the support of MEP Sirpa Pietikainen (EPP, Finland) Platform of Plasma Protein Users is …

Read More

Z Factor crosses from idea to AATD gene treatment

Z Factor, the Cambridge-based drug development company created by European life sciences-oriented venture capital company Medicxi in partnership with the University of Cambridge in 2015, …

Read More

Alpha-1 Around The Globe

Click on the country flags below to learn more about country specific contact and general information, access to care, and available resources